• Skip to main content
  • Skip to secondary menu
  • Skip to footer

Israel News

#Israel: Israel in social media

  • About
  • Support Us
  • Tech Jobs
  • Contact

Kitov Closes $6.0 Million Public Offering

March 17, 2020 By admin

TEL-AVIV, March 17, 2020 — Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced the closing of its previously announced public offering of 20,000,000 units at a price to the public of $0.30 per unit, for gross proceeds of $6.0 million, before deducting placement agent fees and other offering expenses payable by Kitov. Each unit contains one American Depositary Shares (“ADS”) (or ADS equivalent) and one warrant to purchase one ADS. Each ADS represents one ordinary share, no par value, of Kitov. The ADSs (or ADS equivalents) and warrants included in the units were purchased together in the offering, but were issued separately and are immediately separable. The warrants have an exercise price of $0.325 per ADS and will be exercisable at any time after the date of issuance and will expire five years from the date of issuance.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

Kitov intends to use the net proceeds of this offering to fund the development of its oncology drug candidates, acquisition of new assets and for general working capital purposes.

The offering was made under an effective registration statement on Form F-1 (File No. 333-235729) filed with the Securities and Exchange Commission (the “SEC”) and declared effective on March 11, 2020. The offering was made only by means of a prospectus forming part of the effective registration statement. The final terms of the offering are disclosed in a final prospectus filed with the SEC and made available on the SEC’s website at www.sec.gov. Electronic copies of the final prospectus relating to the offering may also be obtained by contacting H.C. Wainwright & Co., 430 Park Avenue, New York, NY 10022, by telephone at (646) 975-6996 or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Kitov
Kitov Pharma (Kitov Pharma Ltd.; NASDAQ/TASE: KTOV) is a clinical-stage company focusing on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, to create successful long-lasting treatments for people with cancer. Kitov’s oncology pipeline includes NT-219 and CM-24. NT-219 is a small molecule targeting the novel cancer drug resistance pathways IRS1/2 and STAT3. Kitov is currently advancing NT-219 in combination with cetuximab as a third-line or second-line treatment option for the treatment of recurrent and metastatic squamous cell carcinoma of head & neck cancer (SCCHN), as well as a single agent monotherapy treatment in patients with advanced solid tumors. CM-24 is a monoclonal antibody blocking CEACAM1, a novel immune checkpoint that supports tumor immune evasion and survival through multiple pathways. Kitov intends to advance CM-24 as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC). Kitov has entered into a clinical collaboration agreement with Bristol Myers Squibb Company (NYSE:BMY) for the planned Phase 1/2 clinical trials to evaluate the combination of CM-24 with the PD-1 inhibitor nivolumab (Opdivo®). Kitov is also the owner of Consensi™, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension which was approved by the FDA for marketing in the U.S and is expected to be launched in the U.S. during 2020 by its partner Coeptis Pharmaceuticals. Kitov has also partnered to commercialize Consensi in China and South Korea. The company is headquartered in Tel Aviv, Israel.

Source: Kitov Pharma Ltd.

Filed Under: Featured Posts Tagged With: IPO, Kitov

Footer

Recent Posts

  • The Proliferation of Ring-Necked Parakeets in Israel: A Complex Ecological Challenge
  • Voyantis Redefines Growth Strategy with $41M Funding Round Led by Intel Capital
  • A pogrom in the streets of Amsterdam
  • WITH ANTISEMITISM AT AN ALL-TIME HIGH, JUST AHEAD OF KRISTALLNACHT, IMMERSIVE XR EXPERIENCE LAUNCHES, GIVING VIEWERS UNPRECEDENTED LOOK INSIDE A PIVOTAL MOMENT IN THE HOLOCAUST
  • UN chief Antonio Guterres just now mourned a mass murderer who oversaw the kidnapping of Hersh Goldberg-Polin
  • Good Morning from Haifa!
  • Haifa’s Empty Beaches Amid Ongoing Conflict with Hezbollah
  • Gloryless Fall of Sinwar: From Hiding to Oblivion
  • Genetic study suggests that Columbus was Jewish
  • The time has come for to remove the UNIFIL soldiers from Hezbollah strongholds

Media Partners

  • Cybersecurity Market
  • Media Partners
Becrypt Achieves Exceptional Growth Through Innovation and Customer-Centric Security Solutions
Active Roles Wins 2025 Cybersecurity Excellence Award for Hybrid Active Directory Protection
Barcelona Cybersecurity Congress 2025: Shaping the Future of Industrial Digital Security
ARMO Launches First Cloud App Detection and Response to Unify Code to Cloud Runtime Security
IGEL and Omnissa Strengthen Endpoint Management and Security Integration
CYREBRO Recognized in Gartner Emerging Tech Report for Detection and Response Startups
Alli AI Announces Upcoming Public Launch of AI-Powered Content Creation Platform
INE Secures Spot in G2’s 2025 Top 50 Education Software Rankings
Barcelona Cybersecurity Congress Spotlights Women’s Impact in STEM and Cybersecurity
Court Dismisses Criminal Charges Against VPN Executive, Affirms No-Log Policy
MSL
Photo Contest
Side Hustle Art
S3H
Analysis
Media Gallery
VPNW
Prints
Blockchaining
Domain Aftermarket

Media Partners

  • Defense Market
  • Media Partners
Epsilor Unveils Groundbreaking High Voltage Military Battery System Based on Standard NATO 6T Batteries
The 6th edition of the Portugal Air Summit 2022, October 12 – 15, 2022, PONTE DE SOR, Portugal
Elbit Systems Ltd. has been awarded contracts $760 million for the supply of ammunition to the Israeli Ministry of Defense
CACI to acquire Azure Summit Technology for $1.275 billion
BlueHalo to Provide U.S. Army with Full-Cycle Support for High Energy Laser Systems
The U.S. Air Force unveiled the B-21 Raider Friday in Palmdale, California
DAF Hosts 3rd Annual Virtual Women’s Air and Space Power Symposium for Professional Development and Empowerment, March 8-10, 2023
V2X Secures $103 Million Contract for U.S. Navy C-26 Aircraft Maintenance
Does recession impact defense industry?
Saronic Secures $175 Million in Series B Funding, Reaches $1 Billion Valuation
VPNW
Virtual Travel Guide
Press Club
Publishing House
Press Media Release
Agile Soft Dev
Renewability
Photography
Domain Market Research
Bootstrapping

Copyright © 2015 IsraelNews.org

Technologies, Market Analysis & Market Research Reports

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT